All In MedTech

Device Trial Radar · NCT07008768

The Purpose is to Evaluate Visual Acuity for Distance, Intermediate and Near and Additionally Contrast Sensitivity at 25% and 10% of Illumination After Implantation of Trifocal IOL, Extended Range of Vision IOL, Bifocal IOL With Low Addition and Monofocal IOL

Visual Outcome After Implantation of Three Different Presbyopia-correcting IOLs and Monofocal IOL

Last checked: Nov 19, 2026Latest source record: Jun 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 131 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

131

Actual

Start

Jan 1, 2018

Primary completion

Oct 31, 2020

Study completion Mar 30, 2022

Sponsor

Lead sponsor
University Eye Hospital SvjetlostAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 6, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated device
No
Who can join
All sexes, from 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study was to evaluate the effect of intraocular lens (IOL) selection on visual acuity and refractive outcomes, to assess the impact of IOL type on postoperative contrast sensitivity, and to investigate whether IOL choice influences the induction and dynamics of higher-order ocular aberrations following cataract surgery/refractive lens exchange surgery in hyperopic patients.

Conditions

  • Cataract
  • Presbyopia Correction
  • Visual Acuity

Interventions

  • Cataract surgery and refractive lens exchange surgeryProcedure

    Cataract surgery or refractive lens exchange surgery was performed with standard phacoemulsification procedure using micro coaxial surgical technique. After superior clear corneal incision, anterior capsulorexis and lens phacoemulsification, the IOL was implanted into the capsular bag using an injector in all cases. Ophthalmic Viscosurgical Device (OVD) was completely removed by irrigation and aspiration. All incisions were self-closing.

  • TRIFOCAL IOLDevice

    1-piece aspheric hydrophobic presbyopia-correcting intraocular lens, trifocal

  • EROV IOLDevice

    1-piece aspheric hydrophobic presbyopia-correcting intraocular lens, extended range of vision (EROV)

  • BIFOCAL IOLDevice

    1-piece aspheric hydrophobic presbyopia-correcting intraocular lens, bifocal with low addition

  • MONOFOCAL IOLDevice

    Control lens: 1-piece aspheric hydrophobic monofocal aspheric IOL

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Uncorrected and Corrected Visual Acuity changes for distance, intermediate, and near in all four groups during the follow upTime frame: 12 months
  2. Higher-order aberration changes in all four groups during the follow upTime frame: 12 months
  3. Contrast sensitivity changes at 25% and 10% illumination in all four groups during the follow upTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Univestity Eye Hospital Svjetlost

    Zagreb, Croatia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.